HK1049352A1 - 一種新穎的脫氧核糖核酸編碼多肽prost-ets - Google Patents

一種新穎的脫氧核糖核酸編碼多肽prost-ets

Info

Publication number
HK1049352A1
HK1049352A1 HK03101484.8A HK03101484A HK1049352A1 HK 1049352 A1 HK1049352 A1 HK 1049352A1 HK 03101484 A HK03101484 A HK 03101484A HK 1049352 A1 HK1049352 A1 HK 1049352A1
Authority
HK
Hong Kong
Prior art keywords
prost
ets
polypeptide
novel
dna encoding
Prior art date
Application number
HK03101484.8A
Other languages
English (en)
Inventor
Harkins Richard
J Lin Richard
Luke May
Monteclaro Felipe
Parkes Deborah
Parry Gordon
Steinbrecher Renate
Toy Van Heuit Pamela
Xuan Jian-Ai
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HK1049352A1 publication Critical patent/HK1049352A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK03101484.8A 1999-11-30 2003-02-28 一種新穎的脫氧核糖核酸編碼多肽prost-ets HK1049352A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16818299P 1999-11-30 1999-11-30
US71815900A 2000-11-21 2000-11-21
PCT/US2000/042295 WO2001042472A2 (en) 1999-11-30 2000-11-29 DNA ENCODING A NOVEL PROST-Ets POLYPEPTIDE

Publications (1)

Publication Number Publication Date
HK1049352A1 true HK1049352A1 (zh) 2003-05-09

Family

ID=26863872

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03101484.8A HK1049352A1 (zh) 1999-11-30 2003-02-28 一種新穎的脫氧核糖核酸編碼多肽prost-ets

Country Status (6)

Country Link
EP (1) EP1234037A2 (zh)
JP (1) JP2003533177A (zh)
AU (1) AU4306401A (zh)
HK (1) HK1049352A1 (zh)
NO (1) NO20022542L (zh)
WO (1) WO2001042472A2 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867731B2 (en) 1998-11-04 2011-01-11 Novartis Vaccines And Diagnostics, Inc. HX2004-6 polypeptide expressed in cancerous cells
WO2000070092A1 (en) 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer
EP1573024A4 (en) 2001-04-10 2007-08-29 Agensys Inc NUCLEIC ACIDS AND SUITABLE PROTEINS SUITABLE FOR THE TREATMENT AND EVIDENCE OF VARIOUS CANCER DISEASES
TWI570662B (zh) * 2016-04-27 2017-02-11 國立彰化師範大學 基因合成教學系統及其方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265565B1 (en) * 1998-04-03 2001-07-24 Incyte Genomics, Inc. Prostate associated Ets protein
US20010010934A1 (en) * 1998-07-31 2001-08-02 Towia Aron Libermann Prostate derived ets factor
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2000070092A1 (en) * 1999-05-14 2000-11-23 Chiron Corporation Expression of ets-domain proteins in cancer

Also Published As

Publication number Publication date
AU4306401A (en) 2001-06-18
EP1234037A2 (en) 2002-08-28
NO20022542D0 (no) 2002-05-29
WO2001042472A3 (en) 2002-05-10
JP2003533177A (ja) 2003-11-11
WO2001042472A2 (en) 2001-06-14
NO20022542L (no) 2002-07-29

Similar Documents

Publication Publication Date Title
PT1214097E (pt) Ácidos nucleicos que codificam polipéptidos de poliepitopos
GB9923177D0 (en) Novel polypeptide
AU8441801A (en) Novel polypeptide
PL340374A1 (en) Tanatin encoding gene
HK1049352A1 (zh) 一種新穎的脫氧核糖核酸編碼多肽prost-ets
GB9923889D0 (en) Novel polypeptide
EP1162269A4 (en) NEW POLYPEPTIDE
HK1048495A1 (zh) 脫氧核糖核酸編碼的prost07多肽
GB9924951D0 (en) Novel polypeptide
EP1179540A4 (en) NEW POLYPEPTIDES
GB9923893D0 (en) Novel polypeptide
GB9923890D0 (en) Novel polypeptide
GB9924960D0 (en) Novel polypeptide
GB9925115D0 (en) Novel polypeptide
GB9923888D0 (en) Novel polypeptide
EP1225220A4 (en) DNA encoding ENDO-BETA galactosidase
EP1354947A4 (en) NEW POLYPEPTIDE
GB9924956D0 (en) Novel polypeptide
GB9923896D0 (en) Novel polypeptide
GB9927787D0 (en) Novel polypeptide
GB9925666D0 (en) Novel polypeptide
GB9925641D0 (en) Novel polypeptide
GB9925113D0 (en) Novel polypeptide
GB9923892D0 (en) Novel polypeptide
GB9924953D0 (en) Novel polypeptide